Tenofovir alafenamide
As of the edition of 20 October 2026, Tenofovir alafenamide is a small molecule: marketed, first approved in 2015 (US); US protection ends in 2032.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2018
- Kind
- Small molecule
- Brand name
- Genvoya
- First approved
- 5 November 2015 (US)
- Approvals on record
- 23 in 4 regions
- Holder of the most recent approval
- Gilead Sciences; 8 holders in all
- Registered trials
- 173, 18 stopped early
- Disease areas
- Infections; Digestive system; Urinary and reproductive; Immune system; Chemically induced; Mental health
US protection
US protection ends in 2032.
The last listed US drug-substance patent ends in 2032. The application that gives this date is held by Gilead Sciences.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product7 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 7 listings behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 37 | 8 | 9 | 1 |
| Phase 1 | 30 | 22 | 3 | 4 |
| Phase 2 | 33 | 19 | 2 | 8 |
| Phase 3 | 22 | 16 | 3 | 2 |
| Phase 4 | 51 | 16 | 12 | 3 |
| All trials | 173 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Gilead Sciences | Applicant and Lead sponsor of trials | 2002 to now |
| Johnson & Johnson | Applicant, Later holder and Lead sponsor of trials | 2015 to now |
| Japan Tobacco | Applicant | 2016 to now |